Join our team here at EvolveImmune Therapeutics!
Looking to make a difference in cancer research? Explore career opportunities at EvolveImmune Therapeutics! We are leading the way in precision cancer medicines for better patient outcomes. Join us in shaping the future of cancer treatment. #EvolveImmune #biotechnology #immunooncology #careers #CancerResearch
Unlocking the Secrets of Cancer Metabolism: Dive into the latest brochure exploring the power of Seahorse Real-Time Cell Metabolic Analysis in cancer research and therapeutic development. Discover how this cutting-edge technology can illuminate metabolic vulnerabilities and drive advancements in cancer drug development. Explore the applications of a real-time metabolic analysis platform for cancer research and cell therapeutics development. Contact us now at marketing@medispec.in or 77188 10037 to learn more! #medispec #cellmetabolism #seahorse #cancerresearch #cellanalysis #drugdevelopment
The adoption of metabolomics in preclinical research is crucial for understanding the complex metabolic pathways in cancer. This understanding can lead to the development of more effective and safer treatment strategies, ultimately enhancing clinical outcomes. Check out our most recent blog to learn more: https://hubs.li/Q02gXpQH0 Key Points: ~Metabolomics Overview: This approach involves analyzing small molecule metabolites to gain insights into the biochemical activities of cells and tissues in cancer. ~Biomarker Identification: Metabolomics assists in discovering specific metabolite signatures associated with various cancer types, potentially leading to early diagnosis and personalized treatment strategies. ~Efficacy and Safety Assessment: By tracking metabolic changes induced by therapeutic agents, metabolomics aids in evaluating the effectiveness and toxicity of cancer treatments in preclinical studies. #CancerResearch #Metabolomics #PreclinicalStudies #TD2
Exosomes, nanosized vesicles released from cells, are gaining popularity as drug delivery vehicles due to their ability to escape liver homing and undesired accumulation. Bovine milk/colostrum-derived exosomes, functionalized for cancer therapeutics, show promise, including validation of anti-tumor efficacy. Check out this free webinar by our friends at Spectral Instruments Imaging on June 11, at 10 AM PDT (12 PM CDT / 1 PM EDT), and learn how milk exosomes can be utilized for targeted drug delivery & the latest advancements in RNA & DNA delivery using the Exosome-PEI-Matrix (EPM) technology: https://lnkd.in/dbPmmX-y #Oncology #Exosomes #Milk #Imaging #PreclinicalImaging
💡 Join Crown Bioscience for an upcoming webinar to explore the significant hurdle of cancer drug resistance, one of the greatest challenges in developing effective cancer therapeutics. 💊 Dr. Rajendra Kumari will discuss the evolving landscape of drug resistance, focusing on preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights. Attendees will gain insights into specific models developed to study resistance to targeted therapies and immunotherapeutics, along with their features and practical applications for predicting clinical outcomes. ➡️ Learn more + register here: https://buff.ly/4eagwr7 #DrugDevelopment #DrugDiscovery #DrugResistance #Oncology #TherapeuticAreas #OncologyDrugDevelopment #CancerTherapy #PreClinical #CellAndGeneTherapies
Could #metabolomics be the missing piece needed to advance your #preclincal #cancertherapy. Translational Drug Development (TD2) latest blog post may help shed light on this valuable capability. Message me or post a comment if you would like to learn more.
The adoption of metabolomics in preclinical research is crucial for understanding the complex metabolic pathways in cancer. This understanding can lead to the development of more effective and safer treatment strategies, ultimately enhancing clinical outcomes. Check out our most recent blog to learn more: https://hubs.li/Q02gXpQH0 Key Points: ~Metabolomics Overview: This approach involves analyzing small molecule metabolites to gain insights into the biochemical activities of cells and tissues in cancer. ~Biomarker Identification: Metabolomics assists in discovering specific metabolite signatures associated with various cancer types, potentially leading to early diagnosis and personalized treatment strategies. ~Efficacy and Safety Assessment: By tracking metabolic changes induced by therapeutic agents, metabolomics aids in evaluating the effectiveness and toxicity of cancer treatments in preclinical studies. #CancerResearch #Metabolomics #PreclinicalStudies #TD2
👇We’re excited to share an article in @ONCOLife on "How Engineered Viruses Could Transform Cancer Treatment." https://lnkd.in/gu9tW4XW 🔍TILT-123 is genetically modified to specifically target and destroy #cancer cells. 💉IV administration of TILT-123 increases patient access, simplifies logistics, and targets cancer metastases more effectively. 👩⚕️Ongoing Phase 1B trials in ovarian and lung cancer in combination with pembrolizumab have the potential to redefine cancer treatment. @American Society of Clinical Oncology (ASCO), @Hüseyin Kandemir #Biotech #Pharma #Innovation #Oncology #ClinicalTrials https://lnkd.in/dTyHEfu9
This World Cancer Day, Inhibrx honors the global commitment to cancer research, celebrating progress and acknowledging the journey ahead. Our mission is to discover and develop effective biologic therapeutics for people with life-threatening conditions, including cancer. Today, we reflect on the importance of continuous innovation and collaboration in the quest to conquer cancer. #Inhibrx #BioTechnology #WorldCancerDay
Today on #WorldCancerResearchDay, we proudly stand with the global scientific community to underscore the critical role that research plays in improving cancer survival rates and enhancing the quality of life for patients and their families. At Zymeworks, we are deeply committed to the belief that continued research, innovation, and scientific advancement can profoundly impact the lives of cancer patients. As we advance our pipeline of multifunctional therapeutics, we honor our exceptional team of researchers, experts, and partners who are dedicated to harnessing the potential of antibody-drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) to address high unmet needs in the treatment of difficult-to-treat cancers. Together, we are driving innovation within #cancerresearch and remain unwavering in our commitment to making a meaningful difference. #AntibodyDrugConjugates #MultifunctionalTherapeutics #Biotech #DrugDevelopment #DrugDiscovery #CancerAwareness #Oncology #ResearchandDevelopment
IOS-1002 is a multi-functional agent based on a naturally occurring human leukocyte antigen that targets multiple immune checkpoints ( LILRB1 (ILT2), LILRB2 (ILT4) and KIR3DL1) to activate both innate and adaptive immune cells. IOS-1002 (formerly iosH2) is described as an open format (peptide free conformation) and expression- and stability-optimized HLA-B57-B2m-IgG4_Fc fusion protein.
I’m thrilled to share the publication of my latest article alongside the brilliant team at ImmunOs Therapeutics AG!. Our article explores the novel use of HLA molecules as cancer therapeutics, providing insights on the development and pre-clincal work of IOS-1002. It’s been an honor to lead this project alongside such a dedicated group of professionals. This piece of research represents not only years of hard work, but it also represents a significant milestone in the journey of bringing novel concepts of immunotherapy from bench to bedside. IOS-1002 is currently tested in Phase I clinical trials for diverse cancer indications. I invite you to read our article and share your insights. https://lnkd.in/eVfXAcZ2 #Innovation #Research #Immunotherapy #benchtobedside #Biotech
Immunotherapies have transformed cancer treatment, but considerable challenges remain. At Mural Oncology, we are using our advanced protein engineering capabilities to broaden the potential and reach of cytokine-based immunotherapies for people with cancer. Our lead candidate, nemvaleukin, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities. It is currently in two potentially registrational trials reading out next year. Discover our pipeline and learn about the clinical trials evaluating nemvaleukin: https://bit.ly/49hUu3c #biotechnology #oncology #drugdevelopment
